Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | AKT2 | P31751 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 10/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1454236 | 0.94 | PIM1 (0.50) | PIM1AKT2EGFRERBB2ERBB4 | |
| SCHEMBL1454641 | 0.93 | PIM1 (0.58) | PIM1AKT2EGFRINSRLCK | |
| SCHEMBL1455689 | 0.91 | PIM1 (0.50) | PIM1AKT2EGFRKDR | |
| SCHEMBL1454779 | 0.90 | EGFR (0.45) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL1455761 | 0.90 | PIM1 (0.50) | PIM1AKT2EGFRKDR | |
| SCHEMBL1455211 | 0.89 | PIM1 (0.50) | PIM1AKT2EGFRINSRLCK | |
| SCHEMBL1455683 | 0.88 | EGFR (0.54) | EGFRKDRERBB2ERBB4ABCG2 | |
| SCHEMBL1455346 | 0.88 | PIM1 (0.48) | PIM1AKT2EGFRSRCKDR | |
| SCHEMBL1454484 | 0.85 | NPC1 (0.42) | PIM1AKT2EGFRERBB2ERBB4 | |
| SCHEMBL1454698 | 0.84 | BRAF (0.51) | LCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PIM1 2963/4885AKT2 3903/4885EGFR 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.